CCCC 8-K SEC Filing Analysis

Latest settled — T+5d

CCCC ▲ +8.39% at T+5d

NEUTRAL call ✓ call won +8.39% · α vs SPY +6.77% · entry $3.22 → $3.49

Next anchor: T+20d in 5d

Last close $3.59 (close Jun 8) · +11.49% from $3.22 entry

Entry anchored
May 15, 2026
via day open

T+1d

-3.42%

call -3.42% · α -2.77%

$3.11

settled 23d ago

T+5d

+8.39%

call +8.39% · α +6.77%

$3.49

settled 19d ago

T+20d

—

call — · α —

—

in 5d

T+60d

—

call — · α —

—

in 2mo

Price Chart

Loading chart...

Executive Summary

C4 Therapeutics disclosed the departure of Chief Accounting Officer Mark Mossler, effective May 15, 2026, with no disagreement cited. CFO Kendra R. Adams has been appointed as the new principal accounting officer without additional compensation. This is a routine internal role consolidation, not a red-flag departure.

Actionable Insight

This is a routine internal role consolidation with no financial or operational implications. The recent DEFA14A proxy solicitation (April 29) suggests board-level activity, but this filing is unrelated. No trading action warranted.

Key Facts

Mark Mossler will cease serving as Chief Accounting Officer effective May 15, 2026.
Departure is explicitly stated as not due to any disagreement with the company or board on financial reporting, operations, policies, or practices.
CFO Kendra R. Adams has been designated as the new principal accounting officer, effective May 15, 2026.
Adams will receive no additional compensation for assuming the principal accounting officer role.
A DEFA14A proxy filing from April 29, 2026 (16 days prior) indicates recent contested election or solicitation activity.

Financial Impact

No financial impact. Role consolidation with no compensation change.

Risk Factors

No material risks identified from this filing alone.

Market Snapshot

Exchange

Nasdaq

Sector

Biological Products, (No Diagnostic Substances)

Analyst Consensus

93% bullish (14 analysts)

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

Document	Accession Number
8-K Filing (Primary)	0001628280-26-035542
Document: 0001628280-26-035542-index-headers.html	0001628280-26-035542
Document: 0001628280-26-035542-index.html	0001628280-26-035542
Document: 0001628280-26-035542.txt	0001628280-26-035542

8 reports for CCCC

T+1T+5T+20T+60

100% Hit rate 4 of 4 directional calls best @ T+60▲ +26.62%Feb 26, 2026

Filters

Reports for CCCC — sortable, filterable
	Type				Now
May 15, 2026 25d ago	8-K NEUTRAL ★ 2/10	$3.22 $3.49	▲ +8.39%	▲ +6.77%	$3.59 (+11.49%)
May 12, 2026 28d ago	8-K NEUTRAL ★ 4/10	$3.17 $3.22	▲ +1.58%	▲ +1.50%	$3.59 (+13.25%)
May 12, 2026 28d ago	Press Release MIXED ★ 5/10	$3.17 $3.22	▲ +1.58%	▲ +1.50%	$3.59 (+13.25%)
Apr 9, 2026 8w ago	8-K BULLISH ★ 7/10	$2.83 $2.90	▲ +2.47%	▼ −0.71%	$3.59 (+26.86%)
Apr 9, 2026 8w ago	Press Release BULLISH ★ 7/10	$2.83 $2.90	▲ +2.47%	▼ −0.71%	$3.59 (+26.86%)
Mar 25, 2026 10w ago	Press Release NEUTRAL ★ 5/10	$2.69 $2.70	▲ +0.37%	▲ +0.62%	$3.59 (+33.46%)
Feb 28, 2026 14w ago	Institutional Cluster BULLISH ★ 6/10	$3.17 $3.59	▲ +13.25%	▲ +14.46%	$3.59 (+13.25%)
Feb 26, 2026 14w ago	8-K BULLISH ★ 7/10	$2.78 $3.03	▲ +8.99%	▲ +10.12%	$3.59 (+29.14%)

US Market Status

Market Closed — Opens in 7h 19m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access